@article{a4cad563133043ae86426ef4c2f32bd7,
title = "Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature",
abstract = "Waldenstr{\"o}m macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is often differentiated from myeloma based on the presence of lytic bone lesions (LBL). However, WM/LPL can present with LBL, and management is poorly understood. We describe a case of an 81-year-old woman with LPL who presented with LBL and was successfully treated with chemoimmunotherapy.",
author = "Mizba Baksh and Liuyan Jiang and Unnati Bhatia and Victoria Alegria and Taimur Sher and Vivek Roy and Asher Chanan-Khan and Sikander Ailawadhi and Parrondo, {Ricardo D.}",
note = "Funding Information: S.A receives honoraria from Celgene and Takeda, as well as research funding from Amgen, Janssen, Pharmacyclics, Cellectar, Bristol Myers Squibb, Medimmune and Phosplatin Publisher Copyright: {\textcopyright} 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd.",
year = "2021",
month = dec,
doi = "10.1002/ccr3.5181",
language = "English (US)",
volume = "9",
journal = "Clinical Case Reports",
issn = "2050-0904",
publisher = "John Wiley and Sons Ltd",
number = "12",
}